Mikkel Thy Thomsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mikkel Thy Thomsen has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Lapat Polasko
Department of Urology, Stanford University School of Medicine, Stanford, California
10 shared publications - Amato J. Giaccia
Department of Oncology, University of Oxford, Oxford, UK
10 shared publications - Chun-Lung Chiu
Department of Veterinary Medicine, College of Veterinary Medicine National Pingtung University of Science and Technology Neipu Township Pingtung County Taiwan
10 shared publications - Dalin Zhang
Department of Urology, Stanford University, Stanford, CA 94305, USA
10 shared publications - Donna M. Peehl
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
10 shared publications - Eric E. Peterson
Department of Urology, Stanford University School of Medicine, Stanford, USA
10 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Society for Neuroscience in eneuro
- Vol. 13 (7)
Limited Contribution of the Lactate Receptor HCAR1 to Exercise-Induced Behavioral and Hippocampal Adaptations
Physical exercise influences hippocampal function and behavior, and lactate has emerged as a candidate signaling molecule linking metabolic activity to neuroplasticity. One proposed mediator is the hydroxycarboxylic acid receptor 1 (HCAR1), but its contribution to behavioral and hippocampal adaptations to exercise remains unclear. We combined studies of HCAR1 knock-out (KO) mice with analyses of human postmortem hippocampal tissue to assess whether HCAR1 is required for behavioral or synaptic responses to exercise and to characterize its spatial distribution in the human hippocampus. Wild-type and HCAR1 KO mice of either sex underwent a 3 week high-intensity interval treadmill program or sedentary handling. Behavioral responses were assessed using the splash test and three-chamber sociability assay, and dentate gyrus (DG) field recordings evaluated synaptic transmission and excitability. In parallel, HCAR1 expression was quantified in the hippocampal tissue from individuals with major depressive disorder (MDD) and nondepressed controls. Exercise reduced grooming and increased locomotion similarly across genotypes, indicating largely preserved behavioral responses in the absence of HCAR1. HCAR1 KO control mice exhibited delayed initiation of social interaction, not observed in exercised mice. Electrophysiology revealed subtle genotype-dependent differences in DG responsiveness following exercise, without major changes in short-term plasticity. In the small available cohort, HCAR1 showed a predominantly perivascular distribution across hippocampal subregions in both MDD and control cases. Together, these findings indicate that HCAR1 is not required for the primary behavioral and synaptic outcomes measured here following exercise, while leaving open a contribution to more specific aspects of hippocampal function under these or other conditions.
- 14 July 2026
- Published by Society for Neuroscience in eneuro
- Vol. 13 (7)
Open AccessLimited Contribution of the Lactate Receptor HCAR1 to Exercise-Induced Behavioral and Hippocampal Adaptations
Physical exercise influences hippocampal function and behavior, and lactate has emerged as a candidate signaling molecule linking metabolic activity to neuroplasticity. One proposed mediator is the hydroxycarboxylic acid receptor 1 (HCAR1), but its contribution to behavioral and hippocampal adaptations to exercise remains unclear. We combined studies of HCAR1 knock-out (KO) mice with analyses of human postmortem hippocampal tissue to assess whether HCAR1 is required for behavioral or synaptic responses to exercise and to characterize its spatial distribution in the human hippocampus. Wild-type and HCAR1 KO mice of either sex underwent a 3 week high-intensity interval treadmill program or sedentary handling. Behavioral responses were assessed using the splash test and three-chamber sociability assay, and dentate gyrus (DG) field recordings evaluated synaptic transmission and excitability. In parallel, HCAR1 expression was quantified in the hippocampal tissue from individuals with major depressive disorder (MDD) and nondepressed controls. Exercise reduced grooming and increased locomotion similarly across genotypes, indicating largely preserved behavioral responses in the absence of HCAR1. HCAR1 KO control mice exhibited delayed initiation of social interaction, not observed in exercised mice. Electrophysiology revealed subtle genotype-dependent differences in DG responsiveness following exercise, without major changes in short-term plasticity. In the small available cohort, HCAR1 showed a predominantly perivascular distribution across hippocampal subregions in both MDD and control cases. Together, these findings indicate that HCAR1 is not required for the primary behavioral and synaptic outcomes measured here following exercise, while leaving open a contribution to more specific aspects of hippocampal function under these or other conditions.
- Open Access
- 6 May 2026
- Published by Wiley in Liver International Communications
- Vol. 7 (2) , e70043
Temporal Biomolecular Processes Underlying Recovery Following 90% Partial Hepatectomy: A Proteomics Study in Rats
Background: Post‐hepatectomy liver failure (PHLF) remains a limitation in the surgical treatment of liver cancer. The 90% partial hepatectomy (PH) rat model reliably induces biochemical PHLF and high mortality, providing a unique platform for identifying molecular pathways necessary for successful liver regeneration. This study aimed to characterize the early biomolecular mechanisms that support recovery following 90% PH. Methods: Rats underwent 90% PH or sham surgery and were euthanised at 12, 24 or 48 h. A validated distress scoring system distinguished recovering animals from those progressing toward fatal PHLF. Liver tissue was analysed using high‐resolution LC–MS/MS proteomics to identify differentially regulated proteins and enriched pathways, and selected targets (Fga, Vegfa) were validated by Western blotting. Results: At 12 h, recovering PH animals exhibited a pronounced acute‐phase response with significant upregulation of innate immune response ( p < 0.01), inflammatory response ( p < 0.0001), haemostatic ( p < 0.0001) and angiogenic pathways ( p < 0.01). At 24 h—the critical survival window—proteins regulating apoptosis signalling ( p < 0.01) and cellular stress ( p < 0.01) were significantly modulated. By 48 h, pathways related to RNA metabolism ( p < 0.001) and hepatocyte proliferation ( p < 0.04) were prominently upregulated. Western blotting confirmed increased expression of Fga and Vegfa, consistent with the proteomic data. Conclusion: Recovery from 90% PH follows a tightly coordinated temporal sequence: an immediate acute inflammatory and coagulative response, followed by regulated apoptosis during the vulnerable 12–24‐h window, and the subsequent induction of hepatocellular proliferation. These findings identify molecular programs associated with recovery that stabilize hepatic function and enable the onset of regeneration. Insights from these temporal mechanisms may guide future biomarker development and therapeutic strategies to reduce PHLF after major liver resection.
- 6 May 2026
- Published by Wiley in Liver International Communications
- Vol. 7 (2) , e70043
Open AccessTemporal Biomolecular Processes Underlying Recovery Following 90% Partial Hepatectomy: A Proteomics Study in Rats
Background: Post‐hepatectomy liver failure (PHLF) remains a limitation in the surgical treatment of liver cancer. The 90% partial hepatectomy (PH) rat model reliably induces biochemical PHLF and high mortality, providing a unique platform for identifying molecular pathways necessary for successful liver regeneration. This study aimed to characterize the early biomolecular mechanisms that support recovery following 90% PH. Methods: Rats underwent 90% PH or sham surgery and were euthanised at 12, 24 or 48 h. A validated distress scoring system distinguished recovering animals from those progressing toward fatal PHLF. Liver tissue was analysed using high‐resolution LC–MS/MS proteomics to identify differentially regulated proteins and enriched pathways, and selected targets (Fga, Vegfa) were validated by Western blotting. Results: At 12 h, recovering PH animals exhibited a pronounced acute‐phase response with significant upregulation of innate immune response ( p < 0.01), inflammatory response ( p < 0.0001), haemostatic ( p < 0.0001) and angiogenic pathways ( p < 0.01). At 24 h—the critical survival window—proteins regulating apoptosis signalling ( p < 0.01) and cellular stress ( p < 0.01) were significantly modulated. By 48 h, pathways related to RNA metabolism ( p < 0.001) and hepatocyte proliferation ( p < 0.04) were prominently upregulated. Western blotting confirmed increased expression of Fga and Vegfa, consistent with the proteomic data. Conclusion: Recovery from 90% PH follows a tightly coordinated temporal sequence: an immediate acute inflammatory and coagulative response, followed by regulated apoptosis during the vulnerable 12–24‐h window, and the subsequent induction of hepatocellular proliferation. These findings identify molecular programs associated with recovery that stabilize hepatic function and enable the onset of regeneration. Insights from these temporal mechanisms may guide future biomarker development and therapeutic strategies to reduce PHLF after major liver resection.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Supplementary Table S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Supplementary Table S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Primary antibodies used for immunohistochemistry (IHC), immunofluorescence (IF), and western blotting (WB)
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Primary antibodies used for immunohistochemistry (IHC), immunofluorescence (IF), and western blotting (WB)
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S1. The levels of murine serum GAS6 before treatment in the LuCaP 147 PDX model. There were no significant differences in murine serum GAS6 levels among groups detected by ELISA
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S1. The levels of murine serum GAS6 before treatment in the LuCaP 147 PDX model. There were no significant differences in murine serum GAS6 levels among groups detected by ELISA
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S6. IHC staining (continuing Fig. 6A) demonstrates batiraxcept alone or in combination with docetaxel reduced p-ERK1/2 protein levels compared to vehicle-treated controls in intratibial LuCaP 147CR PDX model while total AKT proteins levels were similar. Scale bar = 10 μm.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S6. IHC staining (continuing Fig. 6A) demonstrates batiraxcept alone or in combination with docetaxel reduced p-ERK1/2 protein levels compared to vehicle-treated controls in intratibial LuCaP 147CR PDX model while total AKT proteins levels were similar. Scale bar = 10 μm.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S2. Batiraxcept and docetaxel alone or in combination significantly inhibited bone tumor growth and metastasis in LuCaP mPCa AC PDX models. A-B, Representative images of Masson-Goldner staining and Ku70 IHC of PDX cells in the tibiae of LuCaP 147 (A), and LuCaP 35 (B). Human PCa cells marked by Ku70 were significantly decreased after 30 days of treatment by intraperitoneal injection with batiraxcept (20 mg/kg/QOD, n = 8–9, docetaxel (10 mg/kg/QW, n = 9) or the combination of batiraxcept (20 mg/kg/QOD, n = 9) and docetaxel (10 mg/kg/QW, n = 9) compared to vehicle controls (n = 8,10). C-D, Quantification of the IHC Ku70-positive areas in mouse tibia specimens treated with vehicle, batiraxcept, docetaxel, and batiraxcept + docetaxel in A-B. Fold change: combination batiraxcept and docetaxel (B+D) group set as 1. E, Inhibition of LuCaP 147CR tumor cells metastasis to mouse lung lobes by batiraxcept, docetaxel, and batiraxcept + docetaxel combination therapy. The arrowheads indicate Ku70-positive metastatic tumor nodules in the lung, which metastasized from the mice tibiae. F, Quantification of fold changes (docetaxel group set as 1) of human-specific GAPDH level normalized against universal GAPDH level in different treatment groups for LuCaP 147CR. *, p < 0.05; **, p < 0.01; ***, p < 0.001; NS, p > 0.05 not significant. All scale bar = 50 μm.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S2. Batiraxcept and docetaxel alone or in combination significantly inhibited bone tumor growth and metastasis in LuCaP mPCa AC PDX models. A-B, Representative images of Masson-Goldner staining and Ku70 IHC of PDX cells in the tibiae of LuCaP 147 (A), and LuCaP 35 (B). Human PCa cells marked by Ku70 were significantly decreased after 30 days of treatment by intraperitoneal injection with batiraxcept (20 mg/kg/QOD, n = 8–9, docetaxel (10 mg/kg/QW, n = 9) or the combination of batiraxcept (20 mg/kg/QOD, n = 9) and docetaxel (10 mg/kg/QW, n = 9) compared to vehicle controls (n = 8,10). C-D, Quantification of the IHC Ku70-positive areas in mouse tibia specimens treated with vehicle, batiraxcept, docetaxel, and batiraxcept + docetaxel in A-B. Fold change: combination batiraxcept and docetaxel (B+D) group set as 1. E, Inhibition of LuCaP 147CR tumor cells metastasis to mouse lung lobes by batiraxcept, docetaxel, and batiraxcept + docetaxel combination therapy. The arrowheads indicate Ku70-positive metastatic tumor nodules in the lung, which metastasized from the mice tibiae. F, Quantification of fold changes (docetaxel group set as 1) of human-specific GAPDH level normalized against universal GAPDH level in different treatment groups for LuCaP 147CR. *, p < 0.05; **, p < 0.01; ***, p < 0.001; NS, p > 0.05 not significant. All scale bar = 50 μm.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Data from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Purpose:After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in prostate cancer and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed.Experimental Design:Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by IHC staining. We evaluated the effects of a novel soluble AXL signaling inhibitor, sAXL (batiraxcept or AVB-S6-500), on tumor growth and lung metastases in prostate cancer patient-derived xenograft models that were implanted intratibially. After injection of LuCaP cells into the tibiae, tumors were treated with batiraxcept and docetaxel or carboplatin alone or in combination, and tumor growth was monitored by serum prostate-specific antigen or bioluminescence. Tumor burden was quantified by human-specific Ku70 staining, and metastasis to the lungs was determined using qPCR. Transcriptomic profiling, Western blotting, and immunohistochemistry were performed to identify treatment-regulated gene and protein profile changes.Results:High AXL phosphorylation in human prostate cancer bone metastases correlated with shortened survival. Batiraxcept alone or in combination with docetaxel or carboplatin significantly suppressed intratibial tumor growth and suppressed metastasis to the lungs through multiple mechanisms, including repression of cancer stemness genes (CD44, ALDH1A1, TACSTD2, and ATXN1) and the PI3K, JAK, MAPK, and E2F1/NUSAP1 signaling pathways.Conclusions:Our study provides a robust preclinical rationale and mechanisms of action for using batiraxcept as a single agent or in combination with docetaxel or carboplatin to treat lethal metastatic prostate cancer.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Purpose:After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in prostate cancer and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed.Experimental Design:Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by IHC staining. We evaluated the effects of a novel soluble AXL signaling inhibitor, sAXL (batiraxcept or AVB-S6-500), on tumor growth and lung metastases in prostate cancer patient-derived xenograft models that were implanted intratibially. After injection of LuCaP cells into the tibiae, tumors were treated with batiraxcept and docetaxel or carboplatin alone or in combination, and tumor growth was monitored by serum prostate-specific antigen or bioluminescence. Tumor burden was quantified by human-specific Ku70 staining, and metastasis to the lungs was determined using qPCR. Transcriptomic profiling, Western blotting, and immunohistochemistry were performed to identify treatment-regulated gene and protein profile changes.Results:High AXL phosphorylation in human prostate cancer bone metastases correlated with shortened survival. Batiraxcept alone or in combination with docetaxel or carboplatin significantly suppressed intratibial tumor growth and suppressed metastasis to the lungs through multiple mechanisms, including repression of cancer stemness genes (CD44, ALDH1A1, TACSTD2, and ATXN1) and the PI3K, JAK, MAPK, and E2F1/NUSAP1 signaling pathways.Conclusions:Our study provides a robust preclinical rationale and mechanisms of action for using batiraxcept as a single agent or in combination with docetaxel or carboplatin to treat lethal metastatic prostate cancer.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S3. Mouse serum PSA after treatment for 30 days. Batiraxcept and docetaxel as single agents or in combination significanty reduced mouse serum PSA detected by ELISA.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S3. Mouse serum PSA after treatment for 30 days. Batiraxcept and docetaxel as single agents or in combination significanty reduced mouse serum PSA detected by ELISA.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S4. Quantification of bone mineral density in mouse tibia specimen after treatment for 30 days. Batiraxcept and docetaxel as single agents or in combination increased bone mineral density (BMD) of the tibiae to a similar extent as determined by microCT.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S4. Quantification of bone mineral density in mouse tibia specimen after treatment for 30 days. Batiraxcept and docetaxel as single agents or in combination increased bone mineral density (BMD) of the tibiae to a similar extent as determined by microCT.